

2022

**Initial Clinical Experience with NIPT for Rare Autosomal Aneuploidies and Large Copy Number Variations**

Thomas Harasim, Teresa Neuhann, Anne Behnecke, Miriam Stampfer, Elke Holinski-Feder, Angela Abicht  
<https://doi.org/10.3390/jcm11020372>

2015

**47 patients with FLNA associated periventricular nodular heterotopia.**

Lange M, Kasper B, Bohring A, Rutsch F, Kluger G, Hoffjan S, Spranger S, Behnecke A, Ferbert A, Hahn A, Oehl-Jaschkowitz B, Graul-Neumann L, Diepold K, Schreyer I, Bernhard MK, Mueller F, Siebers-Renelt U, Belez-Meireles A, Uyanik G, Janssens S, Boltshauser E, Winkler J, Schuierer G, Hehr U. *Orphanet J Rare Dis.* 2015;10:134. doi:[10.1186/s13023-015-0331-9](https://doi.org/10.1186/s13023-015-0331-9)

**Genetische Syndrome mit Seh- und Hörbehinderungen.**

Moog U, Burau K, Behnecke A, Rohrschneider K. In: *Med Men Geist Mehrf Beh.* Vol 12. ; 2015:15-23.

2013

**Delayed primary diagnosis of LEOPARD syndrome type 1.**

Staub J, Behnecke A, Leverkus M. *J Am Acad Dermatol.* 2013;68(2):e58-60. doi:[10.1016/j.jaad.2012.08.037](https://doi.org/10.1016/j.jaad.2012.08.037)

2012

**Silver-Russell syndrome due to maternal uniparental disomy 7 and a familial reciprocal translocation t(7;13).**

Behnecke A, Hinderhofer K, Jauch A, Janssen JWG, Moog U. *Clin Genet.* 2012;82(5):494-498. doi:[10.1111/j.1399-0004.2011.01792.x](https://doi.org/10.1111/j.1399-0004.2011.01792.x)

**Molecular and clinical characterization of an in frame deletion of uncertain clinical significance in the BRCA2 gene.**

Rath MG, Fathali-Zadeh F, Langheinz A, Tchatchou S, Voigtländer T, Heil J, Golatta M, Schott S, Drasseck T, Behnecke A, Burgemeister A-L, Evers C, Bugert P, Junkermann H, Schneeweiss A, Bartram CR, Sohn C, Sutter C, Burwinkel B. *Breast Cancer Res Treat.* 2012;133(2):725-734. doi:[10.1007/s10549-011-1917-0](https://doi.org/10.1007/s10549-011-1917-0)

**How fingers and face can be the clue?**

Behnecke A, Dikow N, Moog U. *Eur J Neurol.* 2012;19(3):e27-28. doi:[10.1111/j.1468-1331.2011.03622.x](https://doi.org/10.1111/j.1468-1331.2011.03622.x)

**Humangenetische Diagnostik und Beratung: Seltene Erkrankungen in der Pränatalmedizin.**

Moog U, Dikow N, Gaspar H, Behnecke A, Schenk JP, Flechtenmacher C, Beedgen B, Elsässer M. In: *Gynäkologe.* Vol 45. ; 2012:376–382.

2011

**A family with dystrophic alopecia and keratosis pilaris.**

Scholz IM, Hausser I, Behnecke A, Helmbold P. *J Dtsch Dermatol Ges.* 2011;9(12):1055-1056. doi:[10.1111/j.1610-0387.2011.07792.x](https://doi.org/10.1111/j.1610-0387.2011.07792.x)

**Intragenic deletions of IL1RAPL1: Report of two cases and review of the literature.**

Behnecke A, Hinderhofer K, Bartsch O, Nümann A, Ipach M-L, Damatova N, Haaf T, Dufke A, Riess O, Moog U. *Am J Med Genet A.* 2011;155A(2):372-379. doi:[10.1002/ajmg.a.33656](https://doi.org/10.1002/ajmg.a.33656)

2009

**IgE-mediated allergen gene vaccine platform targeting human antigen-presenting cells through the high-affinity IgE receptor.**

Behnecke A, Li W, Chen L, Saxon A, Zhang K. *J Allergy Clin Immunol.* 2009;124(1):108-113. doi:[10.1016/j.jaci.2009.03.020](https://doi.org/10.1016/j.jaci.2009.03.020)

**A novel multi-potential dendritic cell targeted gene vaccination platform; application to food allergy and beyond.**

Zhang K, Behnecke A, Li W, Saxon A. *Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneimittel Langen Hess.* 2009;96:338-347; discussion 348.

2008

**Septal perforation and palatal defect.**

Behnecke A, Aigner T, Rösler W, Schick B. *HNO.* 2008;56(6):623-626. doi:[10.1007/s00106-008-1668-3](https://doi.org/10.1007/s00106-008-1668-3)

**Evaluation of ECP release from intact tissue biopsies from patients with nasal polyps.**

Behnecke A, Mayr S, Schick B, Iro H, Raithel M. *Inflamm Res.* 2008;57 Suppl 1:S65-66. doi:[10.1007/s00011-007-0632-0](https://doi.org/10.1007/s00011-007-0632-0)

2003

**N-methyl-norsalsolinol modulates serotonin metabolism in the rat caudate nucleus: correlation with behavioural changes.**

Thümen A, Behnecke A, Qadri F, Moser A. *Int J Neuropsychopharmacol.* 2003;6(1):35-40. doi:[10.1017/S1461145702003206](https://doi.org/10.1017/S1461145702003206)

2002

**N-methyl-norsalsolinol, a putative dopaminergic neurotoxin, passes through the blood-brain barrier in vivo.**

Thümen A, Behnecke A, Qadri F, Bäuml E, Thümen A, Behnecke CA, Qadri F, Bäuml E, Moser A. *Neuroreport.* 2002;13(1):25-28. doi:[10.1097/00001756-200201210-00010](https://doi.org/10.1097/00001756-200201210-00010)